ArticleJournal of thoracic disease2026
Pericoronary fat attenuation index predicts vulnerable plaque and adverse outcomes in coronary heart disease.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Noncalcified coronary plaque is prone to rupture and may lead to major adverse cardiovascular events (MACEs). The pericoronary fat attenuation index (FAI), derived from coronary computed tomographic angiography (CCTA), is an emerging marker of coronary inflammation. This study aimed to assess the predictive value of the FAI for vulnerable plaque and prognosis in patients with coronary heart disease (CHD). Methods: We retrospectively enrolled 453 patients with CHD who underwent CCTA and were followed for 3 years. Patients were divided into a MACE group (n=103) and a control group (n=350) based on the occurrence of MACEs. The FAI was measured using artificial intelligence software at the site of the most severe coronary stenosis. Clinical characteristics, coronary plaque burden, and FAI were compared between groups. Multivariate logistic regression identified independent predictors of MACEs, and a nomogram prediction model was developed and validated. Results: Patients with MACEs had significantly higher age, greater total and noncalcified plaque burden, lower left ventricular ejection fraction (LVEF), higher FAI, and a greater prevalence of the multivessel disease. Independent predictors of MACEs included age ≥80 years [relative risk (RR) 12.39, 95% confident interval (CI): 5.75-26.69], LVEF <50% (RR 8.73, 95% CI: 4.10-18.58), total coronary plaque burden >33.3% (RR 4.27, 95% CI: 2.23-8.18), increased FAI (RR 1.08, 95% CI: 1.05-1.11), and multivessel disease (RR 3.14, 95% CI: 1.67-5.90) with all P<0.001. The nomogram model demonstrated strong predictive performance, with area under the curve (AUC) values of 0.920 and 0.862 in the training and validation sets, respectively. FAI was significantly correlated with noncalcified plaque burden (r=0.234, P<0.001). Conclusions: FAI is associated with coronary noncalcified plaque burden and is an independent predictor of MACEs in patients with CHD. A prediction model incorporating the FAI demonstrated promising efficacy in identifying high-risk patients, supporting its potential role in personalized risk stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.